IDENTIFICATION OF THE MECHANISMS REGULATING PI3KGAMMA-MEDIATED CONTROL OF CARDIAC CAMP LEVELS AND THEIR INVOLVEMENT IN THE PAGHOGENESIS OF HYPERTROPHIC CARDIOMYOPATHY

Among congenital cardiovascular pathologies, familial hypertrophic cardiomyopathy is one of the most frequent and with the most serious effects. Whereas genes involved in the development of this pathology are known, very limited are the currently available therapies. In patients suffering from this disease, the heart tends to contract less and thus to lose its vital functionality. Paradoxically, however, drugs that stimulate contractility, for example by acting on molecules like cAMP, are not able to exert significant results and, on the contrary, increase mortality. Presently, it is thought that this result is caused by the lack of selectivity of the treatment. In this study, we thus propose to identify the precise mechanisms regulating cAMP metabolism in the heart, with the clear intent to define novel therapeutic approaches, able to overcome the limitation of the current treatments.